LABCORP HOLDINGS INC. LH
NYSE · XNYS · stock · Services-Medical Laboratories
Chart by TradingView
8/9
Piotroski F — financial health
3.39
Altman Z″ — distress risk · safe
27.5%
Dividend payout · safe
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $14.0B | $876.5M | $4.0B | $1.2B | $8.6B |
| 2024 | $13.0B | $746.0M | $3.6B | $1.1B | $8.1B |
| 2023 | $12.2B | $418.0M | $3.4B | $874.1M | $7.9B |
| 2022 | $11.9B | $1.3B | $3.7B | $1.5B | $10.1B |
| 2021 | $13.1B | $2.4B | $5.0B | $2.7B | $10.3B |
| 2020 | $14.0B | $1.6B | $5.0B | $1.8B | $9.4B |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Kyle Kathryn W | EVP, Chief Legal Officer | 2026-06-08 | Sell | 762 | $263.89 |
| Schechter Adam H | President & CEO | 2026-05-11 | Sell | 5,903 | $254.50 |
| Wilkinson Peter J | SVP, Chief Accounting Officer | 2026-03-27 | Sell | 1,633 | $267.05 |
| GRAHAM ANITA Z | EVP, CHRO | 2026-03-26 | Tax withheld | 2,879 | $268.38 |
| GRAHAM ANITA Z | EVP, CHRO | 2026-03-26 | Grant | 6,604 | — |
| Schroeder Mark S | EVP, Pres Diagnostics & COO | 2026-03-26 | Grant | 9,304 | — |
| Schroeder Mark S | EVP, Pres Diagnostics & COO | 2026-03-26 | Tax withheld | 4,600 | $268.38 |
| Schechter Adam H | President & CEO | 2026-03-26 | Tax withheld | 26,106 | $268.38 |
Why these scores methodology →
Piotroski F-score: 8/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 3.39 (safe)
- Working capital / assets 0.065
- Retained earnings / assets 0.47
- EBIT / assets 0.075
- Equity / liabilities 0.884
Source: SEC EDGAR filings · CIK 0000920148 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.